Effectiveness, safety, and versatility of hyaluronic acid dermal filler in patients with reduced midface volume, chin retrusion, and/or loss of jawline contour: A prospective case series study with 12-month follow-up

Objective To investigate the effectiveness, safety, and versatility of injections with the same hyaluronic acid (HA) filler type in patients with signs of aging in the cheeks, chin, and/or jawline. Methods In this single-arm, prospective case series study, patients aged ≥18 years with reduced midface volume, chin retrusion, and/or loss of jawline contour were administered HA filler (Y-Solution® 720 [20 mg/mL]) and followed through 12 months. Main outcomes included midface volume (Midface Volume Loss Rating Scale [MFVLRS]), chin retrusion (Chin Retrusion Rating Scale [CRRS]), loss of jawline contour (Jawline Contour Rating Scale [JCRS]), satisfaction (FACE-Q™ [1, worst; 4, best]), and safety. Results Nineteen patients received a combined total of 33 treatments with HA filler (total volume: 67 mL). The 19 patients demonstrated an immediate improvement in MFVLRS, CRRS, and/or JCRS score from 1–3 at baseline to 0–1 immediately post baseline, which was maintained overall through 12 months (scores 0–3; no attendance, n=7). Satisfaction per FACE-Q was high from 1 month (score 3–4 for all questions, 10/19 patients), which was maintained in a proportion of patients through 12 months (score 3–4 for all questions, 5/19). Adverse events were considered procedural (most common: bruising post treatment, 3/19 patients), did not include swelling, and soon resolved. Conclusion These results indicate that injections of the same HA filler reduced multiple signs of aging in the midface, chin, and/or jawline through 12 months; the injections also resulted in no significant adverse events, including swelling.